Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
As of close of business last night, Sarepta Therapeutics Inc’s stock clocked out at $53.79, down -0.28% from its previous closing price of $53.94. In other words, the price has decreased by -$0.28 from its previous closing price. On the day, 1.91 million shares were traded. SRPT stock price reached its highest trading level at $55.49 during the session, while it also had its lowest trading level at $53.5575.
Ratios:
To gain a deeper understanding of SRPT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 3.18 and its Current Ratio is at 4.20. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.87.
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Wells Fargo on April 11, 2025, initiated with a Overweight rating and assigned the stock a target price of $115.
On April 02, 2025, H.C. Wainwright Upgraded its rating to Neutral which previously was Sell but kept the price unchanged to $75.
RBC Capital Mkts Downgraded its Outperform to Sector Perform on March 31, 2025, whereas the target price for the stock was revised from $161 to $87.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Mar 12 ’25 when Nicaise Claude sold 2,491 shares for $99.64 per share. The transaction valued at 248,203 led to the insider holds 27,812 shares of the business.
Nicaise Claude bought 2,491 shares of SRPT for $248,226 on Mar 12 ’25. On Dec 12 ’24, another insider, Wigzell Hans Lennart Rudolf, who serves as the Director of the company, sold 10,500 shares for $124.84 each. As a result, the insider received 1,310,820 and left with 22,840 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SRPT now has a Market Capitalization of 5233912320 and an Enterprise Value of 5207433216. As of this moment, Sarepta’s Price-to-Earnings (P/E) ratio for their current fiscal year is 22.57, and their Forward P/E ratio for the next fiscal year is 4.22. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.24. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.74 while its Price-to-Book (P/B) ratio in mrq is 3.41. Its current Enterprise Value per Revenue stands at 2.738 whereas that against EBITDA is 20.357.
Stock Price History:
The Beta on a monthly basis for SRPT is 0.89, which has changed by -0.53476906 over the last 52 weeks, in comparison to a change of 0.0635103 over the same period for the S&P500. Over the past 52 weeks, SRPT has reached a high of $173.25, while it has fallen to a 52-week low of $48.01. The 50-Day Moving Average of the stock is -37.31%, while the 200-Day Moving Average is calculated to be -54.34%.
Shares Statistics:
It appears that SRPT traded 1.85M shares on average per day over the past three months and 3137410 shares per day over the past ten days. A total of 96.90M shares are outstanding, with a floating share count of 91.14M. Insiders hold about 6.07% of the company’s shares, while institutions hold 91.93% stake in the company. Shares short for SRPT as of 1743379200 were 6098727 with a Short Ratio of 3.30, compared to 1740700800 on 5064242. Therefore, it implies a Short% of Shares Outstanding of 6098727 and a Short% of Float of 6.5600000000000005.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
